DURAVYU Phase 3 setback leaves EyePoint relying on second pivotal wet AMD trial
DURAVYU misses its Phase 3 wet AMD endpoint despite cutting treatment burden 42%. See why EyePoint’s upcoming LUCIA trial is now critical.
Pharma & Biotech